Blood Thinners and Dental Implant Surgery

Evidence and decision snapshot

Why stopping medication can be more dangerous than bleeding

Anticoagulants reduce formation or propagation of blood clots, while antiplatelet agents reduce platelet activation. They are prescribed for atrial fibrillation, venous thromboembolism, mechanical heart valves, coronary stents, prior stroke, and other conditions. The reason for therapy determines the danger of interruption. A small dental bleed is visible and usually controllable; a clot in the brain, heart, lung, or valve may be sudden and life-threatening.

That is why contemporary dental guidance generally favors continuing therapy for many procedures and using local hemostasis. The implant clinician should not make medication changes based only on fear of bleeding or a standardized office instruction.

How the planned procedure changes risk

One implant placed through a small flap is not the same as eight extractions, bilateral sinus grafts, full-arch implant placement, and immediate conversion of a prosthesis. Bleeding risk rises with the number and location of wounds, flap size, graft harvest, operating time, inflammation, and inability to obtain primary closure. The anterior floor of the mouth also contains vessels where uncontrolled bleeding can threaten the airway, independent of medication use.

When the restorative goal permits, dividing treatment into stages can reduce uncertainty. The clinician can observe hemostasis and healing after a limited procedure before undertaking the next stage. A hospital or ambulatory surgical setting may be appropriate for a medically complex patient undergoing extensive care.

Warfarin and INR

Warfarin effect is measured with the international normalized ratio, or INR. For many dental procedures, treatment can proceed when the INR is within the patient's prescribed therapeutic range, with local hemostatic measures. The appropriate threshold depends on procedure invasiveness, current guidance, and the clinician's setting. An old INR value may not be adequate if health or medication has changed.

Antibiotics, antifungals, changes in diet, acute illness, alcohol use, and liver dysfunction can alter warfarin effect. Communication with the anticoagulation service is useful when the INR is unstable, the planned procedure is extensive, or the indication involves a mechanical valve or very high thromboembolic risk.

Direct oral anticoagulants

Apixaban, rivaroxaban, dabigatran, and edoxaban have relatively predictable dosing but differ in renal clearance, schedule, and pharmacology. For routine dental procedures, many patients do not need interruption. For higher-risk surgery, a clinician may consider timing the procedure at a lower drug level, delaying a dose, or a brief interruption - but only after considering kidney function, indication, and prescriber guidance.

A universal number of hours is unsafe because a twice-daily drug in a patient with normal renal function differs from a renally cleared drug in a patient with advanced kidney disease. The exact last dose, next dose, creatinine clearance, and planned hemostatic strategy should be documented.

Antiplatelet therapy and coronary stents

Aspirin, clopidogrel, prasugrel, and ticagrelor may be used alone or in combination. Dual antiplatelet therapy after coronary stent placement is especially important. Premature discontinuation can lead to stent thrombosis, myocardial infarction, and death. The dentist should contact the cardiologist before considering any change.

Available evidence indicates that bleeding after minor oral surgery while antiplatelet therapy is continued is usually manageable with local measures. The concern is not whether bleeding increases at all, but whether it becomes clinically significant and cannot be controlled. For routine implant procedures, the balance often favors continuation.

Local hemostasis and postoperative instructions

Good hemostasis begins before the incision: control inflammation, understand anatomy, plan flap design, and have sutures and hemostatic agents available. During surgery, use atraumatic technique, identify and control visible bleeding, and avoid leaving a large dead space. Pressure, oxidized cellulose, gelatin sponge, collagen products, fibrin sealants, and antifibrinolytic therapy may be used according to the case.

Patients need clear written instructions, an emergency number, and guidance about what is expected. Persistent bright-red bleeding, rapidly expanding swelling, difficulty swallowing, shortness of breath, dizziness, or bleeding that does not respond to firm pressure requires urgent evaluation. Pain medicines should be selected carefully because nonsteroidal anti-inflammatory drugs can add bleeding risk in some patients.

Frequently asked questions

Should I stop Eliquis before an implant?

Do not decide on your own. Many routine implant procedures can be performed without stopping apixaban, but the answer depends on the procedure, dose, kidney function, and thromboembolic risk.

Is aspirin safe to continue?

For many minor oral surgical procedures, yes. Aspirin is often continued because the cardiovascular risk of interruption can outweigh manageable dental bleeding.

What INR is safe for implant surgery?

There is no single number for every procedure. The INR should be within the prescribed therapeutic range and interpreted with procedure extent and current guidance.

Can I have a bone graft while anticoagulated?

Possibly, but a larger graft may carry more bleeding risk than a straightforward implant. Staging, setting, and medication timing may need coordination.

Are ceramic implants less likely to bleed?

No. Bleeding risk comes from the surgical wound, anatomy, medications, and medical conditions, not from whether the implant fixture is titanium or zirconia.